EMPOWER - BAME vs COVID

Health Disparities Clinical Trial

Official title:

EMPOWER - BAME vs COVID: A Multi-site Clinical Cohort Research Study to Identify Genetic Associations and Candidate Therapeutic Targets to Reduce COVID-19 Morbidity & Mortality Rates in BAME Populations

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04399733
• Other study ID #: EMPOWER-BAME vs COVID
• Status: Withdrawn
• Start date: February 1, 2021
• Est. completion date: February 1, 2024

Study information

• Verified date: August 2021
• Source: Future Genetics Limited
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The COVID-19 virus pandemic has massively affected us all. Moreover, there is a disproportionately high number of COVID-19 severe infections and deaths in British Black, Asian and minority ethnic (BAME) patients. This clinical study plans to discover new ways of protecting people from this virus by looking at our DNA and biology.

Description:

The COVID-19 virus pandemic has massively affected us all. We now know there is a much larger proportion of British Black, Asian and minority ethnic (BAME) patients suffering from COVID-19 infections. This disproportionate level of infection and severity of disease has raised concerns and worries. Other research from April 2020 showed that 71% of the nurses and midwives and 94% of the doctors and dentists that died of COVID-19 infections were from a BAME background despite this group representing 20% and 44% of the workforce respectively. The survival picture is also grim for Black and Asian members of the public where we see disproportionately high rates of deaths. Research estimates that our DNA and the environment equally influence the risk for infection. This clinical study plans to better understand our DNA. Some of the things we will be looking at is age, sex, ethnicity and any illnesses such as diabetes or blood pressure. We will ask people for some spit and look at their medical records. This may help us find some of the reasons why this virus has different effects on people and how we might protect people from COVID-19.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: February 1, 2024
• Est. primary completion date: February 1, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 6 Years and older

Eligibility

Inclusion Criteria:

1. All competent adult and children above the age of 5 years

2. Subjects agree to:

1. Gift saliva (spit) samples

2. Provide Consent for access to medical and health records

Exclusion Criteria:

1. Patient is not registered with the NHS for care.

2. Adults lacking capacity

3. Children under the age of 6 years.

Related Conditions & MeSH terms

• COVID-19, SARS-CoV 2 Infection
• Health Disparities

Locations

Country	Name	City	State
United Kingdom	Future Genetics Limited	Birmingham	West Midlands

Sponsors (1)

Lead Sponsor	Collaborator
Future Genetics Limited

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Identify COVID-19 specific host-defence ("protective") or predisposing ("susceptibility") genetic biomarkers	Discovery of genetic associations with COVID-19 infections that may form the basis of prevention, treatment or management of at-risk BAME groups and the wider population.	30 months
Secondary	Epidemiological profiles of COVID-19 infections in different UK ethnic populations	Measure the variation and extent of the different types of COVID-19 infection in different populations	24 months

External Links

•   FUTURE GENETICS website